Dr. Gallacher started his career in stroke research at Pfizer Central Research, UK, then spent four years at the Royal Free Hospital School of Medicine, University of London in the field of central control of the cardiovascular system.  In 1996, he joined a new company, Quintiles Preclinical in Edinburgh, where he started, developed and managed the in vivo cardiovascular safety research group to become the biggest cardiovascular pharmacology group in the CRO world.  He joined Johnson & Johnson in 2003.